Preoperative immunotherapy for resectable hepatocellular carcinoma: Toward a paradigm shift?

Surgical Treatment After Conversion Therapy in a Patient With Massive Hepatocellular Carcinoma

“…For people in the advanced stage of HCC, antiangiogenic tyrosine kinase inhibitors, anti-VEGF inhibitors, and immune checkpoint inhibitors (including anti-PDL1 and anti-PD1 inhibitors) can be used in clinical practice (Kaseb et al, 2019; Seckler et al, 2020). Tyrosine kinase inhibitors, including sorafenib (Abou-Alfa et al, 2019), regorafenib (Bruix et al, 2017), cabozantinib (Abou-Alfa et al, 2018), and lenvatinib (Kudo et al, 2018), alone or in combination (e.g., sorafenib plus regorafenib [Finn et al, 2018] or sorafenib plus cabozantinib [Kelley et al, 2020]), play an important role in the systemic treatment of HCC.…”

Prospects of molecular hydrogen in cancer prevention and treatment

“…Clinically, tumors often need surgical treatment, so they inevitably face multiple perioperative stress factors such as trauma, anesthesia, and mental stress. Rapidly elevated oxidative stress can lead to an imbalance of internal environmental homeostasis and immune system suppression in tumor patients while promoting tumor recurrence and metastasis (Hsiao et al 2021 ; Matzner et al 2020 ; Seckler et al 2020 ). H 2 has physiological effects of antioxidant, anti-inflammatory, and immune modulation, which can effectively antagonize these unfavorable factors (Sano et al 2018 ) (Fig.…”